The insidious degeneration of white matter and cognitive decline in Fabry disease

Jacob W Johnson1, Hediyeh Baradaran2, Jubel Morgan2

  • 1Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah, United States of America.

Plos One
|November 17, 2025
PubMed

Insights

Fabry disease causes early white matter damage and cognitive decline, distinct from typical brain aging. Quantitative MRI reveals microstructural damage, highlighting the need for cognitive monitoring in aging patients.

Area of Science:

  • Neurology
  • Neuroimaging
  • Genetics

Background:

  • Fabry disease is an X-linked lysosomal storage disorder causing glycolipid accumulation.
  • Neurologic complications include cognitive decline and white matter lesions (WMLs).
  • WMLs in the general population are non-specific, making Fabry-specific changes difficult to discern.

Purpose of the Study:

  • To differentiate Fabry disease-related cognitive decline from typical brain aging.
  • To identify unique factors contributing to cognitive impairment in Fabry disease.
  • To investigate white matter integrity and its relationship with cognition in Fabry patients.

Main Methods:

  • Case-control study comparing 20 Fabry patients with 20 age/sex-matched healthy controls.
  • Utilized neurocognitive assessments and advanced 3.0 T brain MRI techniques (sMRI, qMRI, DTI, BPF imaging).
  • Blinded review of structural MRIs and quantitative analysis of white matter microstructural integrity.

Main Results:

  • Structural MRI features of Fabry disease were indistinguishable from normal aging.
  • Quantitative MRI revealed microstructural white matter damage in younger Fabry adults (<40 yrs).
  • Fabry patients showed age-dependent increases in WML severity and corpus callosum atrophy, alongside trends/significant declines in verbal IQ and executive function.

Conclusions:

  • Early microstructural white matter damage in Fabry disease drives progressive degeneration and cognitive impairment.
  • Fabry-related brain changes are distinct from typical age-related alterations, particularly in younger individuals.
  • Aging Fabry patients may benefit from regular cognitive assessments to address evolving therapeutic needs.

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils03:03

Amyloid Fibrils

6.3K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
498
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
752